Changing paradigm: Neoadjuvant treatment in localised high-risk STS

Speaker: Javier Martin Broto

J.M. Broto elaborates the results from an interim analysis of prospective, randomised study with neoadjuvant anthracycline/ifosfamide chemotherapy in localised high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall as presented at ESMO 2016. Neoadjuvant testing is on good direction to change the treatment paradigm in this setting. He digs also into perspective of other neoadjuvant approaches such as immunomodulation and modulation of tumour microenvironment.

Discussion Points

  1. Rationale for the study
  2. Key study findings
  3. Is neoadjuvant chemotherapy in localised high-risk soft tissue sarcoma going to change the current practice?
  4. What is a perspective of other neoadjuvant approaches in this setting?

Abstract LBA6_PR (ESMO 2016) - Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial